Bausch + Lomb Corporation (BLCO)
After hours:
- Investing.com
Bausch + Lomb explores sale amid parent company's debt woes - report
Bausch + Lomb (NYSE:BLCO) is exploring a potential sale as part of an effort to resolve issues related to its separation from parent company Bausch Health, which is burdened with significant debt, as per a Financial Times report. The move has faced opposition from lenders, including Apollo Global Management (NYSE:APO). “This (sale) makes sense to us given the steep valuation discount between BLCO and its closest eye care peers,” said analysts from Wells Fargo in a note.
- Simply Wall St.
Bausch + Lomb Insider Ups Holding During Year
From what we can see, insiders were net buyers in Bausch + Lomb Corporation's ( NYSE:BLCO ) during the past 12 months...
- GuruFocus.com
Insider Buying: CEO Brent Saunders Acquires Shares of Bausch & Lomb Corp
The transaction was filed with the SEC and indicates a strong signal of confidence from the insider. Following this acquisition, the insider now owns 627,419 shares of Bausch & Lomb Corp. Bausch & Lomb Corp is primarily engaged in the development, manufacture, and marketing of a range of pharmaceutical, medical device, and over-the-counter products, particularly in eye health.
